Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Albert Einstein Healthcare Network
Study ID
NCT05435235
Phase
PHASE4
Status
Suspended

Conditions

  • Acute Kidney Injury
  • Percutaneous Coronary Intervention

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

To compare the incidence of acute kidney injury (AKI) post percutaneous coronary intervention (PCI) in a Dapagliflozin treated group versus a group managed with the usual standard of care.

Key Dates

Start date
Sep 1, 2024
Status verified
Jan 2024
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025

Study Design

Enrollment
250 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Dapagliflozin arm
    Patients who received Dapagliflozin 10 mg daily starting 48h prior to PCI and continuing for 48h post-PCI.
  • No Intervention: Standard of care
    Patients who received the standard of care.

Primary Outcome Measure

Acute Kidney Injury [ Time Frame: Within 7 days. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Einstein Medical CenterPhiladelphiaPennsylvania19141-

Find similar trials in Philadelphia, PA

By research site
Einstein Medical Center· Philadelphia, PA

Related Studies